Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (27)

2024

  1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  2. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

    European Journal of Cancer, Vol. 195

2022

  1. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 14

  2. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182

  3. Immunotherapy for early triple negative breast cancer: research agenda for the next decade

    npj Breast Cancer, Vol. 8, Núm. 1

  4. Rethinking breast cancer follow-up based on individual risk and recurrence management

    Cancer Treatment Reviews, Vol. 109

2021

  1. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495

  2. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review

    JAMA Oncology, Vol. 7, Núm. 12, pp. 1873-1881

  3. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 499-511

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

  2. HER2-Low breast cancer: Pathological and clinical landscape

    Journal of Clinical Oncology, Vol. 38, Núm. 17, pp. 1951-1962

  3. Lucitanib for the treatment of HRþ/HER2- Metastatic breast cancer: Results from the multicohort phase II FINESSE study

    Clinical Cancer Research, Vol. 26, Núm. 2, pp. 354-363

  4. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

    Future Oncology, Vol. 16, Núm. 12, pp. 705-712

  5. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621

2019

  1. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

  2. Window of Opportunity trials for biomarker discovery in breast cancer

    Current Opinion in Oncology, Vol. 31, Núm. 6, pp. 486-492

2018

  1. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

2017

  1. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

    Breast Cancer Research, Vol. 19, Núm. 1